Apollo’s Next Steps: Apply Learnings From Prior Hub-And-Spoke Entities

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Apollo’s $145m financing will help advance its 15-plus candidate portfolio into clinical development. With Patient Square leading the round, its expertise with BridgeBio and co. will help guide Apollo’s evolution.

Two leading hard currencies - US Dollar versus Euro
Apollo's $145m cash raise will help it move toward clinical development

With $145m in new capital, Apollo Therapeutics LLC is looking to move to the next level by taking its 15-plus preclinical programs sourced from three UK universities into clinical development. As Apollo – founded in 2015 as a joint venture of the three universities and AstraZeneca PLC, Johnson & Johnson and GlaxoSmithKline plc – takes this step forward, Patient Square Capital is leading the financing, taking board control and bringing its expertise in the hub-and-spoke business model to the enterprise.

Patient Square managing partner Jim Momtazee previously played a role in funding hub-and-spoke models like BridgeBio Pharma, Inc. and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.